Sugi Predict

Sugi Predict / Targets / GRIA2

GRIA2

Glutamate receptor 2 · P42262 · GRIA2 on Sugi Atlas →

52,388 patent compounds predicted against GRIA2, 30,267 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL90957 SCHEMBL90957 0.53 13/20
Quisqualate Quisqualate (SCHEMBL136819) 0.45 9/20
Nbqx Nbqx (SCHEMBL120375) 1.00 8/20
SCHEMBL90929 SCHEMBL90929 0.39 7/20
SCHEMBL205449 SCHEMBL205449 0.50 5/20
SCHEMBL205450 SCHEMBL205450 0.50 5/20
SCHEMBL28559 SCHEMBL28559 0.45 5/20
SCHEMBL28560 SCHEMBL28560 0.45 5/20
Mimosine Mimosine (SCHEMBL41924) 0.42 5/20
L-Mimosine L-Mimosine (SCHEMBL41925) 0.42 5/20
Gyki-52466 Gyki-52466 (SCHEMBL194854) 1.00 4/20
Gyki-52466 Gyki-52466 (SCHEMBL249675) 0.97 4/20
SCHEMBL121942 SCHEMBL121942 0.64 4/20
SCHEMBL195083 SCHEMBL195083 0.61 4/20
(R,S)-Ampa (R,S)-Ampa (SCHEMBL68799) 0.61 4/20
SCHEMBL38535 SCHEMBL38535 0.47 4/20
SCHEMBL256037 SCHEMBL256037 0.47 4/20
SCHEMBL59810 SCHEMBL59810 0.40 4/20
SCHEMBL118013 SCHEMBL118013 0.80 3/20
SCHEMBL147829 SCHEMBL147829 0.56 3/20

Clinical trials — most relevant to GRIA2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine PHASE4COMPLETED
Effects of the Addition of Metyrapone to Antidepressant Therapy in Depression With Dexamethasone Suppression Test Non-suppression. PHASE4UNKNOWN
Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy PHASE4COMPLETED
TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders PHASE3RECRUITING
Memantine for Refractory OCD Patients PHASE3UNKNOWN
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Robotic Transcranial Magnetic Stimulation for Treatment Resistant Depression: The SPARC-TMS Trial PHASE2/PHASE3NOT_YET_RECRUITING
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia PHASE2COMPLETED
Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders PHASE2COMPLETED
High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia PHASE2UNKNOWN
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder PHASE2COMPLETED
Brain Imaging, Genetics and Treatment for Major Depression PHASE1WITHDRAWN
PET Imaging of Brain mGluR5 Receptors Using [18F]SP203 PHASE1COMPLETED
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial PHASE1COMPLETED
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response PHASE1RECRUITING
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia PHASE1COMPLETED
Antidepressant Effects of NR2B in Major Depression PHASE1COMPLETED
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine EARLY_PHASE1COMPLETED
Tolerability and Efficacy of L-Serine in Patients With GRIN-related Encephalopathy nanUNKNOWN
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease nanCOMPLETED
Acamprosate: Genes Associated With Response nanCOMPLETED
An Assessment of Cognitive Function in Irritable Bowel Syndrome nanUNKNOWN
Development of a Novel Glutamate Receptor Ligand for PET Scans in Neuropsychiatric Systemic Lupus Erythematosus nanCOMPLETED
PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX nanCOMPLETED
Genetic Variants Associated With Adolescent Suicide Attempts nanCOMPLETED
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy) nanUNKNOWN
Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden nanCOMPLETED
Transcriptomic Profile of Patients Treated With Different Modalities of Spinal Cord Stimulation nanUNKNOWN
Memantine in Systemic Lupus Erythematosus nanCOMPLETED
Regulation of Arginine-vasopressin (AVP) nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a GRIA2 binder may also engage these)

ProteinNameSimilarity
P23819 — 1.000 P23819 →
P19491 — 1.000 P19491 →
Q5R4M0 — 1.000 Q5R4M0 →
Q38PU7 — 1.000 Q38PU7 →
Q9Z2W8 — 1.000 Q9Z2W8 →
GRIA4 Glutamate receptor 4 1.000 landscape →
P19492 — 1.000 P19492 →
GRIA1 Glutamate receptor 1 1.000 landscape →
Q38PU5 — 1.000 Q38PU5 →
GRIA3 Glutamate receptor 3 1.000 landscape →
P19490 — 1.000 P19490 →
Q9Z2W9 — 1.000 Q9Z2W9 →
Q38PU8 — 1.000 Q38PU8 →
P19493 — 1.000 P19493 →
Q38PU6 — 1.000 Q38PU6 →
P23818 — 1.000 P23818 →
P42260 — 0.999 P42260 →
B1AS29 — 0.998 B1AS29 →
P39087 — 0.998 P39087 →
P42264 — 0.998 P42264 →
Q38PU2 — 0.998 Q38PU2 →
Q91755 — 0.998 Q91755 →
P26591 — 0.996 P26591 →
Q38PU3 — 0.996 Q38PU3 →
GRIK2 Glutamate receptor ionotropic, kainate 2 0.996 landscape →
GRIK3 Glutamate receptor ionotropic, kainate 3 0.995 landscape →
Q38PU4 — 0.994 Q38PU4 →
B3LZ39 — 0.994 B3LZ39 →
GRIK1 Glutamate receptor ionotropic, kainate 1 0.994 landscape →
Q60934 — 0.993 Q60934 →